{"id":1872,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2021-07-22","marketCap":214.688,"name":"Absci Corp","phone":"13609491041","outstanding":92.94,"symbol":"ABSI","website":"https://www.absci.com/","industry":"Biotechnology"},"price":2.377175,"year":2023,"month":12,"day":14,"weekday":"Thursday","title":"The Impact of Currency Fluctuations on Absci Corp Multinational Stock","date":"2023-12-14","url":"/posts/2023/12/14/ABSI","content":[{"section":"Introduction","text":"Currency fluctuations refer to the changes in the value of one currency in relation to another. For a multinational corporation like Absci Corp, which operates in multiple countries and deals with various currencies, these fluctuations can have a profound impact on its financial performance and stock value."},{"section":"Positive Impact of Currency Fluctuations","text":"In some cases, currency fluctuations can work in favor of Absci Corp. For example, if the domestic currency of one of Absci Corp's subsidiaries strengthens against the U.S. dollar, the multinational company's reported earnings from that subsidiary will increase when converted back to dollars. This can have a positive impact on the stock price as investors perceive higher profitability."},{"section":"Negative Impact of Currency Fluctuations","text":"On the other hand, currency fluctuations can also have adverse effects. If Absci Corp's domestic currency weakens against the U.S. dollar, the company's imported raw materials and equipment become more expensive. This can lead to increased production costs and lower profit margins. As a result, the stock price may decline as investors anticipate reduced profitability."},{"section":"Case Study 1: Absci Corp and the Depreciation of the British Pound","text":"In 2016, following the Brexit referendum, the British pound experienced a significant depreciation against the U.S. dollar. Absci Corp, which had a subsidiary in the UK, saw a significant decline in the value of its earnings when converted back to dollars. This led to a negative impact on its stock price, as investors reacted to the weakened financial performance."},{"section":"Case Study 2: Absci Corp and the Strengthening of the Swiss Franc","text":"In 2015, the Swiss National Bank removed the Swiss franc's peg to the euro, causing the currency to appreciate rapidly. Absci Corp had significant operations in Switzerland and benefited from the strengthening franc. The increased value of the Swiss subsidiary's earnings, when converted to dollars, boosted Absci Corp's overall financial performance and ultimately resulted in an upward trend in its stock price."},{"section":"Conclusion","text":"Currency fluctuations pose both risks and opportunities for Absci Corp's multinational stock. While a stronger domestic currency can enhance profitability and stock value, a weaker domestic currency can lead to increased costs and reduced investor confidence. Accurate management of currency risk through hedging strategies and careful monitoring of global economic factors is crucial for mitigating potential negative impacts."}],"tags":["CrossOver55","Long","Biotechnology"],"news":[{"category":"company","date":1702349160,"headline":"Absci management to meet virtually with William Blair","id":124472057,"image":"","symbol":"ABSI","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3253770678"},{"category":"company","date":1702296840,"headline":"The 10 Stocks Using AI To Develop New Drugs Were Up 4%, On Average, Last Week","id":124439639,"image":"","symbol":"ABSI","publisher":"TalkMarkets","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3250997212"},{"category":"company","date":1702209960,"headline":"KeyBanc sees opportunity in tech-enabled drug discovery stocks","id":124425548,"image":"","symbol":"ABSI","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3250517857"},{"category":"company","date":1701781860,"headline":"Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy","id":124302259,"image":"https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","symbol":"ABSI","publisher":"Yahoo","summary":"Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.","url":"https://finance.yahoo.com/news/absci-absi-astrazeneca-deal-design-131100484.html"},{"category":"company","date":1701748260,"headline":"Absci initiated with bullish view at KeyBanc, here's why","id":124318878,"image":"","symbol":"ABSI","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241946919"},{"category":"company","date":1701693000,"headline":"Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate","id":124281944,"image":"https://s.yimg.com/ny/api/res/1.2/iZHy.xV2iRvKCCXe_8m4EQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0zNTI-/https://media.zenfs.com/en/globenewswire.com/b1ee56ea230741fd72ddfa61fd4270ec","symbol":"ABSI","publisher":"Yahoo","summary":"Collaboration Combines Absci’s AI Antibody Drug Creation Platform with AstraZeneca’s Expertise in Oncology Research and DevelopmentVANCOUVER, Wash., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a leader in generative AI antibody discovery, today announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed antibody against an oncology target. This collaboration combines Absci's Integrated Drug Creation™ platform with AstraZeneca'","url":"https://finance.yahoo.com/news/absci-announces-collaboration-astrazeneca-advance-123000837.html"},{"category":"company","date":1701685623,"headline":"Absci Shares Rise 27% After Announcing Collaboration With AstraZeneca","id":124277222,"image":"","symbol":"ABSI","publisher":"Finnhub","summary":"By Chris Wack Absci shares were up 27% at $2.21 after the company entered into a collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target. The stock hit...","url":"https://finnhub.io/api/news?id=f297670f2480cfa4e56371fa67daf36f60cb9577fb10b1cb6e07c5ba48635bd3"},{"category":"company","date":1701680520,"headline":"Ocular Therapeutix, EyePoint Pharmaceuticals among healthcare movers","id":124279670,"image":"","symbol":"ABSI","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240525137"},{"category":"company","date":1701672780,"headline":"AstraZeneca in pact with Absci to develop cancer drug based on AI","id":124280124,"image":"","symbol":"ABSI","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240384838"},{"category":"company","date":1701671580,"headline":"Absci enters collab with AstraZeneca to advance AI-driven oncology candidate","id":124280125,"image":"","symbol":"ABSI","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240366866"},{"category":"company","date":1701669900,"headline":"AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report","id":124280126,"image":"","symbol":"ABSI","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240341889"},{"category":"company","date":1701666060,"headline":"AstraZeneca, Absci tie up on cancer drug, FT reports","id":124280127,"image":"","symbol":"ABSI","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240291215"},{"category":"company","date":1701584875,"headline":"AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT","id":124260701,"image":"https://media.zenfs.com/en/reuters-finance.com/ffdd7373c71dc918eddc7aee96b65778","symbol":"ABSI","publisher":"Yahoo","summary":"The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca, the report said.  It did not say what kind of cancer they plan to target.","url":"https://finance.yahoo.com/news/astrazeneca-ai-biologics-firm-absci-062755722.html"},{"category":"company","date":1701584556,"headline":"UPDATE 1-AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT","id":124260702,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"ABSI","publisher":"Yahoo","summary":"Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday.  The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca, the report said.","url":"https://finance.yahoo.com/news/1-astrazeneca-ai-biologics-firm-062236789.html"},{"category":"company","date":1701579633,"headline":"AstraZeneca ties up with AI biologics company to develop cancer drug","id":124260121,"image":"","symbol":"ABSI","publisher":"Yahoo","summary":"AstraZeneca has signed a deal worth up to $247mn with Absci Corporation of the US to design an antibody to fight cancer, the latest tie-up in fast-expanding efforts to use artificial intelligence for drug discovery.  The collaboration aims to harness Absci’s AI technology for large-scale protein analysis to find a viable oncology therapy — a leading focus of Anglo-Swedish drugmaker AstraZeneca.  The partnership adds to a flurry of agreements between big pharmaceutical companies and young AI businesses to build novel disease treatments and cut the costs of developing them.","url":"https://finance.yahoo.com/m/6c5cbccc-1447-377c-a9ef-33a894d11c87/astrazeneca-ties-up-with-ai.html"}]}